Mesenchymal stem cells as treatment for MS - progress to date.
about
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studiesInduced Stem Cells as a Novel Multiple Sclerosis TherapyMesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis.Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.Are nestin-positive mesenchymal stromal cells a better source of cells for CNS repair?Primary mesenchymal stem cells in human transplanted lungs are CD90/CD105 perivascularly located tissue-resident cells.Bone marrow stromal cells as immunomodulators. A primer for dermatologists.Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE)Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing-remitting multiple sclerosis model.Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma.Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem cells during experimental autoimmune encephalomyelitis.Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells.Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model.Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis modelAllogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell FunctionDisease-modifying treatments for progressive multiple sclerosis.Molecular Mechanisms Mediating Retinal Reactive Gliosis Following Bone Marrow Mesenchymal Stem Cell Transplantation.MSC Therapeutics in Chronic Inflammation.Adipose tissue-derived stromal cells (ADSC) express oligodendrocyte and myelin markers, but they do not function as oligodendrocytes.Sphingosine 1-Phosphate Receptor 2 Regulates the Migration, Proliferation, and Differentiation of Mesenchymal Stem Cells.Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats.Nicotine Augments the Beneficial Effects of Mesenchymal Stem Cell-based Therapy in Rat Model of Multiple Sclerosis.Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis.CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases.Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts.
P2860
Q26750597-27EB2EB3-E9CB-445A-8D87-1D6629E2E76DQ28081780-106B2B02-B26E-4666-9A6F-A47FD7C19CFBQ30690412-12AFE9CD-3744-49F0-9993-73D93B0F8F9FQ33750137-756384CD-5FD3-4F89-BA33-F691D6124964Q33757255-14B936D9-E688-42BE-838F-E25584E7EE9AQ34419649-374A4A66-2E9C-44A3-8A16-8CF703336764Q34961598-96F34F9C-38FB-49CA-8275-9398AC56A84AQ35213818-5FB8E08A-D174-494B-9A69-7453E2E835A8Q35654025-A66AFA3D-8454-429D-A82F-6378B297D3DDQ36071006-4768912C-4B31-49A9-BF44-76A90A5B6494Q36700629-403BFB26-E176-4A26-97DF-D1264A567D4EQ37199722-DBBD1107-5E9C-42DE-A168-1D353DCE300CQ37202733-A3AC8226-5409-40D6-9CD1-66EA8DFF83AFQ37499253-0C609F81-62E9-4FE7-904E-A24CCA12DF4FQ37637831-882021E5-529F-4BEA-A554-4CC2B7C669E7Q38142030-E2305819-43E2-47CF-A2D0-35F147F466F2Q40198530-7E176ACE-8CC1-46D6-93E8-2F6F391EC1F3Q42327942-43DADBAB-6B18-4930-9814-EDCA488F1284Q42511103-2D160C97-46C3-4D24-BFD7-B431137D8CFAQ42746891-9A250ABC-65C7-486A-9E62-62E2A2F48C97Q43242462-15B08CF5-D20A-41EC-942C-8D85E614339CQ46944384-892AD1E9-1ED8-45B5-BCF0-10A18E4FAF28Q47363542-9FF9748A-38E4-4ED1-889D-74F5D4C26582Q49343380-FAFE26CC-D972-4E32-84FC-09D776A72BF5Q49541054-1146A237-5BC4-4DA3-A848-56A04D0A97ADQ54565698-9406D597-9C29-4774-B6E3-5553E2321BB4
P2860
Mesenchymal stem cells as treatment for MS - progress to date.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Mesenchymal stem cells as treatment for MS - progress to date.
@en
type
label
Mesenchymal stem cells as treatment for MS - progress to date.
@en
prefLabel
Mesenchymal stem cells as treatment for MS - progress to date.
@en
P2860
P356
P1476
Mesenchymal stem cells as treatment for MS - progress to date
@en
P2093
Mark S Freedman
P2860
P304
P356
10.1177/1352458512464686
P577
2012-11-01T00:00:00Z